Search Results 1711-1720 of 19116 for Enzyme

  1. Genetic and Epigenetic Drivers of HCC in the Setting of NAFLD - Mayo Clinic Research

    However, 5mC is not stable; it is converted to 5-hydroxymethylcytosine (5hmC) by TET enzymes. 5hmC is now recognized as an epigenetic mark that is distinct ...

  2. Mayo Clinic Minute: How the thyroid affects the heart

    The thyroid is part of the endocrine system and regulates your body's metabolic rate. It is a small gland with a complex job. When the thyroid is not ...

  3. Publications - Arturo M. Valverde, M.D. - Mayo Clinic

    2006; 27(4):374-88. Dzeja PP, Bast P, Ozcan C, Valverde A, Holmuhamedov EL, Van Wylen DG, Terzic A. Targeting nucleotide-requiring enzymes: implications for ...

  4. Prostate-Specific Membrane Antigen (PSMA) in Hepatocellular Carcinoma - Mayo Clinic Research

    This project in the Developmental Research Program in the Mayo Clinic Hepatobiliary SPORE studies PSMA as a potential diagnostic and therapeutic target in ...

  5. Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients with Pancreatic Cancer That Has Been Removed by Surgery - Mayo Clinic

    Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays ...

  6. S1406 A Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer - Mayo Clinic

    Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies ...

  7. Pazopanib Hydrochloride in Treating Patients with Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma - Mayo Clinic

    Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

  8. A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF - Mayo Clinic

    ... enzymes). If treated for hepatitis C viral eradication, then a viral load below the limits of quantitative detection for at least 12 weeks must be ...

  9. Nizubaglusta in Late-Infantile and Juvenile Forms of Niemann-Pick Type C Disease and GM1 Gangliosidosis or GM2 Gangliosidosis - Mayo Clinic

    ... enzyme activity test showing values lower than the normal laboratory range. GM2AB diagnosis with unknown significance variants will be acceptable if ...

  10. Active Removal of IntraCerebral Hematoma Via Active Irrigation - Mayo Clinic

    Mild activation of systemic fibrinolysis, implying passage of the enzyme from ventricle to blood, occurred 4 to 6 hours after each intraventricular injection, ...